,92 Whether CCS patients with type 4a MI, who are not already on ACE-inhibitors (for heart failure, hypertension, or diabetes) or beta-blockers (for left ventricular dysfunction or systolic heart failure), would benefit from the addition of these drugs for reducing the risk of future MACE is not known, and needs to be evaluated in time to come studies. Here, ACE is linked to heart failure.